Ibrutinib-associated focal segmental glomerulosclerosis and the impact of podocin mutations in chronic lymphocytic leukemia
Czogalla J, Schliffke S, Lu S, Schwerk M, Petereit H, Zhang T, Liu S, Dumoulin B, Gies S, Wu G, Hänzelmann S, Bode M, Grahammer F, Gödel M, Voigtländer M, Butt L, Bokemeyer C, Bergmann C, Benzing T, Wiech T, Puelles V, Huber T
KIDNEY INT. 2024;105(4):877-881.

Effect of factor XI inhibition on tumor cell-induced coagulation activation
Mäder J, Rolling C, Voigtländer M, Schulenkorf A, Lehr C, Regenhardt J, Bokemeyer C, Beckmann L, Langer F
J THROMB HAEMOST. 2024;22(1):199-212.

Rivaroxaban bei tumorassoziierter venöser Thromboembolie
Bauersachs R, Voigtländer M, Langer F
DEUT MED WOCHENSCHR. 2022;147(23):1545-1551.

Purpura Fulminans Triggered by the Formation of Anti-Endothelial Autoantibodies in a Patient with Chronic Lymphocytic Leukemia
Beckmann L, Lennartz M, Beitzen-Heineke A, Voigtländer M, Rolling C, Holstein K, Bokemeyer C, Amirkhosravi A, Langer F
Ann Hematol Oncol. 2022;9(1):.

Inhibition of protein disulfide isomerase with PACMA-31 regulates monocyte tissue factor through transcriptional and posttranscriptional mechanisms
Beckmann L, Mäder J, Voigtlaender M, Klingler F, Schulenkorf A, Lehr C, Regenhardt J, Bokemeyer C, Ruf W, Rolling C, Langer F
THROMB RES. 2022;220:48-59.

PO-31: The small-molecule FXIa inhibitor, BMS-26208, prevents tumor cell-induced coagulation activation predominantly in tumor entities with lower tissue factor (TF) expression
Mäder J, Voigtländer M, Rolling C, Quick H, Schulenkorf A, Lehr C, Bokemeyer C, Beckmann L, Langer F
THROMB RES. 2022;213(Suppl 2):.

Thromboembolic events in deceased patients with proven SARS-CoV-2 infection: Frequency, characteristics and risk factors
Voigtlaender M, Edler C, Gerling M, Schädler J, Ondruschka B, Schröder A, Sperhake J, Ehrhardt S, Wang L, Haddad M, Kiencke V, Renné T, Roedl K, Kluge S, Wichmann D, Langer F
THROMB RES. 2022;218:171-176.

Management of Vascular Thrombosis in Patients with Thrombocytopenia
Voigtlaender M, Langer F
HAMOSTASEOLOGIE. 2022;42(1):19-28.

62/w mit rezidiviertem Ovarialkarzinom und Luftnot
Voigtländer M, Langer F
ONKOLOGE. 2022;2022(28):144-149.

Gerinnungsstörungen bei Tumorerkrankungen
Voigtländer M, Langer F
DERMATOLOGIE. 2022;73(10):809–819.

Bacitracin and Rutin Regulate Tissue Factor Production in Inflammatory Monocytes and Acute Myeloid Leukemia Blasts
Beckmann L, Rolling C, Voigtländer M, Mäder J, Klingler F, Schulenkorf A, Lehr C, Bokemeyer C, Ruf W, Langer F
CANCERS. 2021;13(16):3941.

Monocyte activation and acquired autoimmune protein S deficiency promote disseminated intravascular coagulation in a patient with primary antiphospholipid syndrome
Beckmann L, Voigtländer M, Holstein K, Lennartz M, Schneider S, Haddad M, Renné T, Bokemeyer C, Rolling C, Langer F
RES PRACT THROMB HAE. 2021;5(5):.

Myeloperoxidase has no effect on the low procoagulant activity of silica-free DNA
Beckmann L, Voigtländer M, Rolling C, Schulenkorf A, Bokemeyer C, Langer F
THROMB RES. 2021;2021(203):36-45.

Prevalence of definite antiphospholipid syndrome in carriers of the JAK2V617F mutation
Janjetovic S, Beckmann L, Holstein K, Rolling C, Thiele B, Schafhausen P, Schön G, Bokemeyer C, Langer F, Voigtlaender M
THROMB RES. 2021;198:55-61.

LPS-induced expression and release of monocyte tissue factor in patients with haemophilia
Holstein K, Matysiak A, Witt L, Sievers B, Beckmann L, Haddad M, Renné T, Voigtländer M, Langer F
ANN HEMATOL. 2020;99(7):1531-1542.

Comparison of acetylsalicylic acid and clopidogrel non-responsiveness assessed by light transmittance aggregometry and PFA-100® in patients undergoing neuroendovascular procedures
Rolling C, Tomada J, Frölich A, Holst B, Holstein K, Voigtländer M, Janjetovic S, Haddad M, Renné T, Fiehler J, Bokemeyer C, Rolling T, Langer F
CLIN CHEM LAB MED. 2020;59(2):383-392.

Effect of myeloperoxidase on the anticoagulant activity of low-molecular-weight heparin and rivaroxaban in an in-vitro tumor model
Voigtländer M, Beckmann L, Schulenkorf A, Sievers B, Rolling C, Bokemeyer C, Langer F
J THROMB HAEMOST. 2020;18(12):3267-3279.

Therapie und Prophylaxe der tumorassoziierten venösen Thromboembolie
Voigtländer M, Langer F
InFo Hämatologie + Onkologie. 2020;(06/2020):.

High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers
Rossi A, Voigtländer M, Klose H, Schlüter H, Schön G, Loges S, Paolini M, Bokemeyer C, Reck M, Tarro G, Binder M
J ONCOL. 2019;2019:8970645.

Low-Molecular-Weight Heparin in Cancer Patients: Overview and Indications
Voigtländer M, Langer F
HAMOSTASEOLOGIE. 2019;39(1):67-75.

Antikoagulatorische Therapie bei onkologischen Patienten
Voigtländer M, Lennartz M, Yamamura J, Langer F
J Onkol - Z Onkol Fortb. 2019;2019(1):62-70.

Management of cancer-associated venous thromboembolism - a case-based practical approach
Voigtlaender M, Langer F
VASA. 2018;47(2):77-89.

Lapatinib
Voigtländer M, Schneider-Merck T, Trepel M
Recent Results Cancer Res. 2018;211:19-44.

Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-KPolymorphism
Braig F, Kriegs M, Voigtlaender M, Habel B, Grob T, Biskup K, Blanchard V, Sack M, Thalhammer A, Ben Batalla I, Braren I, Laban S, Danielczyk A, Goletz S, Jakubowicz E, Märkl B, Trepel M, Knecht R, Riecken K, Fehse B, Loges S, Bokemeyer C, Binder M
CANCER RES. 2017;77(5):1188-1199.

Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA
Oberle A, Brandt A, Voigtländer M, Thiele B, Radloff J, Schulenkorf A, Alawi M, Akyüz N, März M, Ford C, Krohn-Grimberghe A, Binder M
HAEMATOLOGICA. 2017;102(6):1105-1111.

Mutational landscape reflects the biological continuum of plasma cell dyscrasias
Rossi A, Voigtländer M, Janjetovic S, Thiele B, Alawi M, März M, Brandt A, Hansen T, Radloff J, Schön G, Hegenbart U, Schönland S, Langer C, Bokemeyer C, Binder M
BLOOD CANCER J. 2017;7(2):e537.

Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
Voigtländer M, Langer F
HAMOSTASEOLOGIE. 2017;37(4):241-255.

Tumorassoziierte venöse Thromboembolien
Voigtländer M, Langer F
Vasomed. 2017;29(3):127-134.

Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma
Braig F, Voigtländer M, Schieferdecker A, Busch C, Laban S, Grob T, Kriegs M, Knecht R, Bokemeyer C, Binder M
ONCOTARGET. 2016;7(28):42988-42995.

Expression and release of platelet protein disulphide isomerase in patients with haemophilia A
Voigtländer M, Holstein K, Spath B, Bokemeyer C, Langer F
HAEMOPHILIA. 2016;22(6):e537-e544.

Right Atrial Thrombosis in Antiphospholipid Syndrome with Secondary Immune Thrombocytopenia
Voigtländer M, Conradi L, Hinsch A, Langer F
THORAC CARD SURG REP. 2015;4(1):40-43.

Clinical Evidence that Coagulation Activation Drives Cancer Progression - a Report of 2 Cases
Voigtländer M, Holstein K, Leuenroth S, Mudter J, Bokemeyer C, Langer F
ONCOL RES TREAT. 2015;38(9):449-52.

Hospital population screening reveals overrepresentation of CD5(-) monoclonal B-cell lymphocytosis and monoclonal gammopathy of undetermined significance of IgM type
Voigtländer M, Vogler B, Trepel M, Panse J, Jung R, Bokemeyer C, Bacher U, Binder M
ANN HEMATOL. 2015;94(9):1559-65.

Lapatinib
Nolting M, Schneider-Merck T, Trepel M
Recent Results Cancer Res. 2014;201:125-43.

An electronic tool for visual feedback to monitor the adherence to quality indicators in intensive care medicine
Kastrup M, Nolting M, Ahlborn R, Braun J, Grubitzsch H, Wernecke K, Spies C
J INT MED RES. 2011;39(6):2187-2200.

Letzte Aktualisierung aus dem FIS: 20.12.2024 - 23:35 Uhr